Our latest Pulse Poll Report reveals candid, real-world insights from rare disease patients across two of our most engaged rare disease communities. These findings uncover the emotional, practical, and clinical factors shaping how patients think about treatment, including:
- What’s delaying treatment starts?
- What motivates patients to switch?
- Who influences their decisions—and where do they turn for trusted guidance?
If you’re preparing your 2026 brand or media plan, this is required reading.
Treatment Decisions Pulse Poll Report
Rare Reach
Bionews has spent over a decade building the largest online network of rare disease communities, reaching an astounding average of 72% of the domestic diagnosed patient population*. Our scale within niche rare disease audiences offers pharmaceutical partners unparalleled access to engaged, highly targeted patients.
50+
Rare Disease
Communities
1+ Million
Rare Disease Patients
Reached Per Month*
72%
Avg. U.S. Rare Disease
Patient Population Reach*
*Avg. monthly domestic reach across top 20 rare disease communities
Rare Audience Quality
Bionews is the #1 online source for rare disease news and community. Our condition-specific communities are trusted destinations for patients and caregivers who are actively researching their diagnosis, exploring treatment options, and seeking peer support.
This intent-driven engagement creates a uniquely qualified audience—deeply informed, highly motivated, and ready to act. For pharmaceutical partners, this means your message reaches patients at precisely the moment they’re making decisions that matter.
#1
Rare Disease News Source
for Patients & Caregivers
87%
Audience is Diagnosed
Patient or Caregiver
47x
Avg. Targeting
Multiple*
*Source: Crossix 2024
Rare Engagement
What sets Bionews apart is the authenticity and trust we’ve earned within our 50+ rare disease communities over the past decade. Our communities are safe, condition-specific spaces where patients come to seek credible clinical information and make informed treatment decisions. This high-intent, research-driven mindset fuels the strongest engagement in the industry—and delivers real impact for our pharmaceutical partners.
4:32
Min Avg.
Session Time
0.22%
Avg. Ad CTR
40%
Avg. Email
Open Rate